Allan M. Gurtan,Shareef Khalid,Christopher Koch,Maleeha Zaman Khan,Lindsey B. Lamarche,Elizabeth Dolan,Ana M. Carrion,Richard Zessis,Matthew E. Clement,Zhiping Chen,Loren D. Lindsley,Yu-Hsin Chiu,Ryan S. Streeper,Daniel P. Denning,Allison B. Goldfine,Brian Doyon,Ali Abbasi,Jennifer L. Harrow,Kazuhisa Tsunoyama,Makoto Asaumi,Ikuyo Kou,Alan R. Shuldiner,Juan L. Rodriguez-Flores,Asif Rasheed,Muhammad Jahanzaib,Muhammad Rehan Mian,Muhammad Bilal Liaqat,Syed Shahzaib Raza,Riffat Sultana,Anjum Jalal,Muhammad Hamid Saeed,Shahid Abbas,Fazal Rehman Memon,Muhammad Ishaq,John E. Dominy,Danish Saleheen

Abstract:Growth differentiation factor 15 (GDF15) is a secreted protein that regulates food intake, body weight, and stress responses in pre-clinical models . The physiological function of GDF15 in humans remains unclear. Pharmacologically, GDF15 agonism in humans caused nausea without accompanying weight loss , and the effect of GDF15 antagonism is being tested in clinical trials to treat cachexia and anorexia. Human genetics point to a role for GDF15 in hyperemesis gravidarum, but the safety or impact of complete GDF15 loss, particularly during pregnancy, is unknown . Here, we characterize GDF15 loss-of-function carriers (LOF), including 5 homozygous null carriers (“knockouts”) from 75,018 participants enrolled in the Pakistan Genomic Resource (PGR) . We tested for the association of GDF15 LOF with 97 quantitative traits and binary outcomes. Further, 3 additional knockouts and 59 heterozygous carriers were identified in recall-by-genotype (RBG) studies accompanied by recruitment of family members. GDF15 knockouts ranged in age from 31 to 75 years, were fertile, and showed no consistent overt metabolic dysfunction. Collectively, our data indicate that (i) complete GDF15 loss is compatible with life and fertility, (ii) chronic therapeutic inhibition of GDF15 may be tolerated, and (iii) GDF15 modulation may not significantly impact body weight or metabolic syndrome.

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper primarily explores the impact of human GDF15 gene loss of function (including complete loss) on human physiology and metabolism, as well as its potential therapeutic significance. Specifically: 1. **Function of the GDF15 Gene**: - GDF15 is a secreted protein that has been shown in mouse experiments to regulate food intake, body weight, and stress response. However, its physiological function in humans remains unclear. - Pharmacological studies indicate that GDF15 agonists cause nausea in humans without accompanying weight loss, while GDF15 antagonists are being tested in clinical trials for the treatment of cachexia and anorexia. 2. **Impact of Complete Loss of GDF15 Gene**: - Through whole-exome sequencing and genotype-based recall studies, the paper identified multiple carriers of GDF15 loss of function (LOF), including 5 individuals with complete loss of function (i.e., "knockout" individuals). - These carriers range in age from 31 to 75 years, have normal fertility, and do not exhibit significant metabolic disorders. - The study found that complete loss of GDF15 function does not affect lifespan or fertility, suggesting that long-term inhibition of GDF15 may be tolerable and that GDF15 regulation may not significantly impact weight or metabolic syndrome. 3. **Functional Validation of GDF15 Variants**: - Researchers validated in vitro that the C211G variant is indeed a loss of function variant and further confirmed this through in vivo experiments. - The study also analyzed the impact of GDF15 LOF variants and the C211G variant in different populations, finding no significant association between these variants and various metabolic indicators. In summary, this paper aims to reveal the physiological role of GDF15 in humans and its potential therapeutic applications by studying naturally occurring carriers of GDF15 loss of function.

Identification and characterization of human GDF15 knockouts

Identification and characterization of human GDF15 knockouts

Humans without GDF15 reassure drug developers

Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation

GDF15 deficiency promotes high fat diet-induced obesity in mice

GDF15 is required for maintaining subcutaneous adipose tissue lipid metabolic signature

GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

GDF15 knockout does not substantially impact perinatal body weight or neonatal outcomes in mice

GDF15 linked to maternal risk of nausea and vomiting during pregnancy

Identification of a Mutation in GDF9 As a Novel Cause of Diminished Ovarian Reserve in Young Women

Complete loss of in humans improves glucose metabolism and beta cell function

GDF15 is dispensable for the insulin-sensitizing effects of chronic exercise

G546A polymorphism of growth differentiation factor-9 contributes to the poor outcome of ovarian stimulation in women with diminished ovarian reserve.

GDF15 promotes weight loss by enhancing energy expenditure in muscle

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer

Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15

The GDF15 3′ UTR Polymorphism rs1054564 Is Associated with Diabetes and Subclinical Atherosclerosis

GDF15 Is Elevated in Conditions of Glucocorticoid Deficiency and Is Modulated by Glucocorticoid Replacement